[go: up one dir, main page]

AR025455A1 - MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES - Google Patents

MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES

Info

Publication number
AR025455A1
AR025455A1 ARP000104536A ARP000104536A AR025455A1 AR 025455 A1 AR025455 A1 AR 025455A1 AR P000104536 A ARP000104536 A AR P000104536A AR P000104536 A ARP000104536 A AR P000104536A AR 025455 A1 AR025455 A1 AR 025455A1
Authority
AR
Argentina
Prior art keywords
contraception
mesoprogestines
conceptives
components
female
Prior art date
Application number
ARP000104536A
Other languages
Spanish (es)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR025455A1 publication Critical patent/AR025455A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de mesoprogestinas para producir un producto farmacéutico para la anticoncepcion femenina, a una preparacion farmacéutica para la anticoncepcionfemenina y a un método anticonceptivo femenino que administra cantidades efectivas de unamesoprogesti na en una mujer que desea contar con anticoncepcion.Opcionalmente, la mesoprogestina puede utilizarse en combinacion con un estrogeno. Las mesoprogestinas se definen como compuestos que disponen de actividadtanto agonística comoantagonística en el r eceptor de progesterona (RP) in vivo. Estabilizan la funcion de RP en un nivel intermedio entre agonístico yantagonístico. Con las progestinas o las antiprogestinas no es posible lograr estados funcionales correspondientes.J867, J912, J956 y J1042 s on lasmesoprogestinas preferibles de acuerdo con la presente.Use of mesoprogestins to produce a pharmaceutical product for female contraception, a pharmaceutical preparation for contraception, and a female contraceptive method that administers effective amounts of unamesoprogestin in a woman who wishes to have contraception.Optionally, mesoprogestin can be used in combination with an estrogen Mesoprogestins are defined as compounds that have agonistic activity as antagonistic in the progesterone receptor (RP) in vivo. They stabilize the RP function at an intermediate level between yantagonistic agonistic. With the progestins or the antiprogestins it is not possible to achieve corresponding functional states.

ARP000104536A 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES AR025455A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
AR025455A1 true AR025455A1 (en) 2002-11-27

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104536A AR025455A1 (en) 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
JP5288796B2 (en) * 2004-07-07 2013-09-11 ワイス・エルエルシー Periodic progestin regimens and kits
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
PL2419108T3 (en) 2009-04-14 2017-08-31 Laboratoire Hra Pharma Method for on-demand contraception
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
DE3888269T2 (en) * 1987-09-24 1994-07-07 Jencap Research Ltd Hormone composition and application.
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4332283A1 (en) 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE4447715C2 (en) 1994-08-09 1998-02-05 Jenapharm Gmbh Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd.
ES2279515T3 (en) * 1994-10-24 2007-08-16 Bayer Schering Pharma Aktiengesellschaft PROGESTERONE COMPETITIVE ANTAGONISTS FOR THE CONTROL OF FEMALE FERTILITY, ORIENTED TO THE NEEDS OF USE.
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
RU2189819C2 (en) * 1996-06-25 2002-09-27 Акцо Нобель Н.В. Schemes for progestogen - antiprogestogen intake
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
CN1353717A (en) * 1999-05-04 2002-06-12 莱加制药公司 Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
BR0013711A (en) 2002-05-07
KR20020038745A (en) 2002-05-23
HUP0202515A2 (en) 2002-12-28
UA77150C2 (en) 2006-11-15
EP1605949A2 (en) 2005-12-21
JP2003511399A (en) 2003-03-25
HUP0202515A3 (en) 2004-06-28
CO5190694A1 (en) 2002-08-29
EA006805B1 (en) 2006-04-28
PL353994A1 (en) 2003-12-15
NO20020998L (en) 2002-03-14
WO2001026603A2 (en) 2001-04-19
HRP20020265A2 (en) 2004-02-29
LV12940B (en) 2003-06-20
CZ2002707A3 (en) 2002-11-13
CA2383650A1 (en) 2001-04-19
NO20020998D0 (en) 2002-02-28
PE20010579A1 (en) 2001-06-04
LT5001B (en) 2003-03-25
EE200200103A (en) 2003-04-15
BG106441A (en) 2002-09-30
MXPA02002186A (en) 2002-09-02
AU3215001A (en) 2001-04-23
AU781835B2 (en) 2005-06-16
LT2002035A (en) 2002-10-25
SI20853A (en) 2002-10-31
WO2001026603A3 (en) 2002-01-17
IL148415A0 (en) 2002-09-12
SK2982002A3 (en) 2002-07-02
CN1384748A (en) 2002-12-11
NZ517470A (en) 2004-03-26
YU13902A (en) 2006-01-16
EA200200284A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CA2256365A1 (en) Compositions, methods and devices for the transdermal delivery of drugs
PT836506E (en) TRANSDERMAL PENSION FOR ADMINISTRATION OF 17-DECACEACY NORGESTIMATE SO OR IN COMBINATION WITH A ESTROGEN
EP1260206A3 (en) Pants-type disposable wearing article
DK1272504T3 (en) 8. Beta-hydrocarbyl-substituted estradiol for use as selective estrogens
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
AR035904A1 (en) 5- [2-HIDROXI-3-1- (3-TRIFLUOROMETILFENIL) -CICLOPROPIL-PROPIONILAMINO] -FTALIDA AND COMPOUNDS RELATED TO PROGESTERONE RECEPTOR MODULAR ACTIVITY
ES2162900T3 (en) L-N-MENTOL LIQUID COMPOSITION AND PROCEDURE FOR PREPARATION.
EA200900451A1 (en) METHOD OF OBTAINING COMPOSITION OF ESTRADIOL WITH SLOW-BREAKDOWN (OPTIONS), ESTRADIOL AND CHOLESTEROL MICROSPHERE AND METHOD FOR SIMULTANEOUS CONTRACEPTION AND HORSE SUBSTITUTION
AR025455A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) AS COMPONENTS OF FEMALE ANTI-CONCEPTIVES
EA200100108A1 (en) APPLICATION OF BIOGENAL SULFAMATS OF ESTROGENS FOR HORMONE-SUBSTITUTE THERAPY
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
AR048722A1 (en) TREATMENT OF DISRUPTION HEMORRAGY IN EXTENDED ANTI-CONCEPTIVE REGIMES
DE3417910C2 (en) Novel hygienic template
BR0214634A (en) Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate
CR10289A (en) "STRATRIENS 9-ALFA-SUBSTITUTED AS SELECTIVE EFFECTIVENESS STROGENS" (DIVISIONAL)
AR025457A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTORS MODULATORS) FOR THE TREATMENT AND PREVENTION OF HORMONE-DEPENDENT BENEFIT GYNECOLOGICAL DISORDERS
AR025456A1 (en) MESOPROGESTINES (PROGESTERONE RECEIVER MODULATORS) AS COMPONENTS OF COMPOSITIONS USED FOR HORMONAL REPLACEMENT THERAPY (HRT)
BR0214334A (en) Method for providing a topical base composition for use in the preparation of a cosmetic composition, resealable cosmetic container, and anhydrous composition
Stockfleth Humane Papillomviren
CN209734269U (en) long service life's fixed plate for bone fracture
CN2452478Y (en) Bandage for hip
KR970005295A (en) Vaginal tablets containing bamboo salt and mica as active ingredients
ATE546144T1 (en) USE OF ESTRADIOLVALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF DYSF UNCTIONAL UTERINE BLEEDING IN UNIT WITH ORAL CONTRACEPTION
Khomasuridze et al. Characteristics of progestin use in pre-menopausal women
BR0010070A (en) Use of org 33245, contraceptive kit, combined means for the measurement of a progestin and an antiprogestogen, and methods of contraception, and for treatment of irregular uterine bleeding or rupture in a female using a progestin-only preparation

Legal Events

Date Code Title Description
FB Suspension of granting procedure